Zanubrutinib (BeiGene) Overview 2019: An Oral Small Molecule Inhibitor of Bruton’s Tyrosine Kinase, Developed to be More Selective with Less Off-Target Effects than Imbruvica – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Zanubrutinib” report has been added to ResearchAndMarkets.com’s offering. Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s…